Trial · NCT06957002
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Failure free survival at Week 52 | 12 months ( Week 52) | A failure is defined by the occurrence of a relapse or the impossibility to decrease Glucocorticoids according to the predefined scheduled Glucocorticoids scheme. |
| Secondary | Proportion of new ischemic event | 12 months (Week 52) | |
| Secondary | Proportion of patients in remission without prednisone | 12 months (Week 52) | Proportion of patients in remission without prednisone |
| Secondary | Proportion of patients in remission with prednisone ≤5 mg/day | 12 months (Week 52) | |
| Secondary | Cumulative dose of prednisone | 12 months (Week 52) | |
| Secondary | Proportion of patient in remission | 2 years | Proportion of patient in remission |
| Secondary | Proportion of patients relapsing | year 1 to year 2 | Proportion of patients relapsing |
| Secondary | Proportion of patients receiving Glucocorticoids | 2 years | |
| Secondary | Quality of life measured by the "Health Assessment Questionnaire" (HAQ) | at Week 26 and Week 52 | HAQ (Health Assessment Questionnaire) is a functional disability tool specific to rheumatoid arthritis. The assessment covers the past week and 8 domains of physical activity. For each area of activity, 2 to 3 items are described. Each item can be modified with aids. Only items with a specified response or aid are taken into account. Scores range from 0 (no impact) to 3 (maximum impact). |
| Secondary | Quality of life measured by the "Short Form 36 Questionnaire" (SF36) | at Week 26 and Week 52 | To score the SF-36, scales are standardized with a scoring algorithm or by the SF-36 (v2) scoring software to obtain a score ranging from 0 to 100. Higher scores indicate better health status, and a mean score of 50 has been articulated as a normative value for all scales |
| Secondary | Frequency and type of side effects | within 1 year after inclusion | Frequency and type of side effects |
| Secondary | Exploratory criteria | At the beginning of the study and in both groups at Week 13 and Week 52 | Compare the remodeling cytokines (pentraxin 3, osteoprotegerin, osteopontin, osteocalcin, thrombomodulin, HGF, endothelin, IL-6, TGF-β MMP-3) |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06957002/registered